Novel agents in the treatment of metastatic colorectal cancer

Stephen Leong, Wells A. Messersmith, Aik-Choon Tan, S. Gail Eckhardt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer death in the United States. Research has led to an explosion of knowledge into the molecular basis of CRC in the past decades. Numerous receptors and intracellular proteins have been identified and implicated in the growth and progression of metastatic CRC, thus creating novel targets for drug development. Many agents are under development and have begun to enter early and even later-stage clinical trials. Results of these agents have demonstrated some encouraging activity but in a small number of patients. Research into predictive biomarkers aims to select the patients who may benefit from these novel agents. This review will address several of these promising new agents, their potential relevance to CRC, results from early clinical studies, and their incorporation into future and ongoing CRC clinical trials. Clearly, there is an urgent need for new agents in this disease, but as we learned from the experience with epidermal growth factor receptor-targeted antibodies, patient selection will be increasingly be required for individualized therapy to become a reality in CRC.

Original languageEnglish
Pages (from-to)273-282
Number of pages10
JournalCancer Journal
Volume16
Issue number3
DOIs
Publication statusPublished - 2010 May 1
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Therapeutics
Clinical Trials
Explosions
Research
Epidermal Growth Factor Receptor
Patient Selection
Cause of Death
Biomarkers
Antibodies
Growth
Pharmaceutical Preparations
Neoplasms
Proteins

Keywords

  • Metastatic colorectal cancer
  • Novel agents
  • Targeted agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Leong, S., Messersmith, W. A., Tan, A-C., & Eckhardt, S. G. (2010). Novel agents in the treatment of metastatic colorectal cancer. Cancer Journal, 16(3), 273-282. https://doi.org/10.1097/PPO.0b013e3181e076c5

Novel agents in the treatment of metastatic colorectal cancer. / Leong, Stephen; Messersmith, Wells A.; Tan, Aik-Choon; Eckhardt, S. Gail.

In: Cancer Journal, Vol. 16, No. 3, 01.05.2010, p. 273-282.

Research output: Contribution to journalArticle

Leong, S, Messersmith, WA, Tan, A-C & Eckhardt, SG 2010, 'Novel agents in the treatment of metastatic colorectal cancer', Cancer Journal, vol. 16, no. 3, pp. 273-282. https://doi.org/10.1097/PPO.0b013e3181e076c5
Leong, Stephen ; Messersmith, Wells A. ; Tan, Aik-Choon ; Eckhardt, S. Gail. / Novel agents in the treatment of metastatic colorectal cancer. In: Cancer Journal. 2010 ; Vol. 16, No. 3. pp. 273-282.
@article{e56f2f911ecb4a16a5e6048b1d563ff5,
title = "Novel agents in the treatment of metastatic colorectal cancer",
abstract = "Colorectal cancer (CRC) is one of the leading causes of cancer death in the United States. Research has led to an explosion of knowledge into the molecular basis of CRC in the past decades. Numerous receptors and intracellular proteins have been identified and implicated in the growth and progression of metastatic CRC, thus creating novel targets for drug development. Many agents are under development and have begun to enter early and even later-stage clinical trials. Results of these agents have demonstrated some encouraging activity but in a small number of patients. Research into predictive biomarkers aims to select the patients who may benefit from these novel agents. This review will address several of these promising new agents, their potential relevance to CRC, results from early clinical studies, and their incorporation into future and ongoing CRC clinical trials. Clearly, there is an urgent need for new agents in this disease, but as we learned from the experience with epidermal growth factor receptor-targeted antibodies, patient selection will be increasingly be required for individualized therapy to become a reality in CRC.",
keywords = "Metastatic colorectal cancer, Novel agents, Targeted agents",
author = "Stephen Leong and Messersmith, {Wells A.} and Aik-Choon Tan and Eckhardt, {S. Gail}",
year = "2010",
month = "5",
day = "1",
doi = "10.1097/PPO.0b013e3181e076c5",
language = "English",
volume = "16",
pages = "273--282",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Novel agents in the treatment of metastatic colorectal cancer

AU - Leong, Stephen

AU - Messersmith, Wells A.

AU - Tan, Aik-Choon

AU - Eckhardt, S. Gail

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Colorectal cancer (CRC) is one of the leading causes of cancer death in the United States. Research has led to an explosion of knowledge into the molecular basis of CRC in the past decades. Numerous receptors and intracellular proteins have been identified and implicated in the growth and progression of metastatic CRC, thus creating novel targets for drug development. Many agents are under development and have begun to enter early and even later-stage clinical trials. Results of these agents have demonstrated some encouraging activity but in a small number of patients. Research into predictive biomarkers aims to select the patients who may benefit from these novel agents. This review will address several of these promising new agents, their potential relevance to CRC, results from early clinical studies, and their incorporation into future and ongoing CRC clinical trials. Clearly, there is an urgent need for new agents in this disease, but as we learned from the experience with epidermal growth factor receptor-targeted antibodies, patient selection will be increasingly be required for individualized therapy to become a reality in CRC.

AB - Colorectal cancer (CRC) is one of the leading causes of cancer death in the United States. Research has led to an explosion of knowledge into the molecular basis of CRC in the past decades. Numerous receptors and intracellular proteins have been identified and implicated in the growth and progression of metastatic CRC, thus creating novel targets for drug development. Many agents are under development and have begun to enter early and even later-stage clinical trials. Results of these agents have demonstrated some encouraging activity but in a small number of patients. Research into predictive biomarkers aims to select the patients who may benefit from these novel agents. This review will address several of these promising new agents, their potential relevance to CRC, results from early clinical studies, and their incorporation into future and ongoing CRC clinical trials. Clearly, there is an urgent need for new agents in this disease, but as we learned from the experience with epidermal growth factor receptor-targeted antibodies, patient selection will be increasingly be required for individualized therapy to become a reality in CRC.

KW - Metastatic colorectal cancer

KW - Novel agents

KW - Targeted agents

UR - http://www.scopus.com/inward/record.url?scp=77953648749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953648749&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e3181e076c5

DO - 10.1097/PPO.0b013e3181e076c5

M3 - Article

VL - 16

SP - 273

EP - 282

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 3

ER -